GLP-1 Agonists Compared: Semaglutide, Tirzepatide, and More
1 min read
Published:
Last updated:
A comprehensive comparison of all major GLP-1 receptor agonists for weight loss, helping you understand which medication best fits your needs.
Complete Medication Comparison
| Medication | Type | Dosing | Weight Loss | Brand Names |
|---|---|---|---|---|
| Tirzepatide | GIP + GLP-1 | Weekly injection | 15-22% | Mounjaro, Zepbound |
| Semaglutide | GLP-1 only | Weekly injection | 12-15% | Ozempic, Wegovy |
| Liraglutide | GLP-1 only | Daily injection | 8-12% | Saxenda, Victoza |
| Dulaglutide | GLP-1 only | Weekly injection | 10-13% | Trulicity |
| Exenatide | GLP-1 only | Daily or weekly | 6-10% | Byetta, Bydureon |
Detailed Medication Profiles
Tirzepatide (Most Effective)
- • Mechanism: Dual GIP + GLP-1 receptor agonist
- • Pros: Highest weight loss, weekly dosing, improved metabolic markers
- • Cons: Higher cost, stronger side effects initially
- • Best For: Maximum weight loss, higher BMI
Semaglutide (Balanced Choice)
- • Mechanism: GLP-1 receptor agonist only
- • Pros: Excellent efficacy, weekly dosing, well-studied
- • Cons: GI side effects, requires titration
- • Best For: Reliable results, moderate weight loss goals
Liraglutide (Daily Option)
- • Mechanism: GLP-1 receptor agonist
- • Pros: Long track record, flexible dosing control
- • Cons: Daily injections, lower weight loss than newer options
- • Best For: Those preferring daily dosing, FDA-approved longest
How to Choose the Right GLP-1
Decision Factors
- • Weight Loss Goals: Higher goals → Tirzepatide; Moderate → Semaglutide
- • Injection Preference: Weekly preferred by most patients
- • Cost Considerations: Compounded versions more affordable
- • Side Effect Sensitivity: Start with lower-dose options
- • Medical History: Discuss with provider for personalized choice
Common Side Effects Across All GLP-1s
- • Nausea (most common, usually temporary)
- • Diarrhea or constipation
- • Decreased appetite
- • Fatigue (especially during titration)
- • Injection site reactions
Scientific References
- Nauck MA, Quast DR, Wefers J, Meier JJ (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism.Read StudyDOI: 10.1016/j.molmet.2020.101102
- Jastreboff AM, Aronne LJ, Ahmad NN (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
- Pi-Sunyer X, Astrup A, Fujioka K (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1411892
TMT
Written by Trimi Medical Team
Our team of healthcare professionals specializes in weight management and metabolic health, providing comprehensive, evidence-based information about GLP-1 medications.
Medical Disclaimer: This comparison is for educational purposes only. Consult with your healthcare provider to determine which GLP-1 medication is appropriate for your individual health needs.